Antiepileptic drug-induced osteopenia in ambulatory epileptic children receiving a standard vitamin D3 supplement

Journal of Pediatric Endocrinology and Metabolism

Volumn 18, Issue 6, 2005, Pages 585-588

  Tekgul, Hasan ^a,b   Dizdarer, Gulsen ^a   Demir, Nilgun ^a   Ozturk, Cihat ^a   Tutuncuoglu, Sarenur ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

Antiepileptic drug; Bone mineral density; Epilepsy; Osteopenia; Vitamin D

Indexed keywords

ALKALINE PHOSPHATASE; ANTICONVULSIVE AGENT; CALCIUM; CARBAMAZEPINE; COLECALCIFEROL; PHENOBARBITAL; PHENYTOIN; PHOSPHORUS; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCULATION; CHILD; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; FEMALE; HUMAN; HYPOCALCEMIA; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OSTEOPENIA; PHOSPHATE BLOOD LEVEL; STUDENT T TEST; TURKEY (REPUBLIC); VITAMIN SUPPLEMENTATION;

EID: 21444452954     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2005.18.6.585     Document Type: Article

References (31)

1. Barden HS, Mazess RB, Chesney RW, Rose PG, Chun R. Bone status of children receiving anticonvulsant therapy. Metal Bone Dis Relat Res 1982; 4: 43-47.
2. Weinstein RS, Bryce GF, Sappington LJ, King DW, Gallagher BB. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984; 58: 1003-1009.
3. Ala-Houhala M, Korpela R, Koivikko M, Koskinen T, Koskinen M, Koivula T. Long-term anticonvulsant therapy and vitamin D metabolism in ambulatory pubertal children. Neuropediatrics 1986; 17: 212-216.
4. Timperlake RW, Cook SD, Thomas KA, Harding AF, Bennett JT, Haller JS, Anderson RM. Effects of anticonvulsant drug therapy on bone mineral density in a pediatric population. J Pediatr Orthop 1988; 8: 467-470.
5. Chung S, Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994; 16: 382-385.
6. Valimaki MJ, Tiihonen M, Laitinen K, Tahtela R, Karkkainen M, Lamberg-Allardt C, Makela P, Tunninen R. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994; 9: 631-637.
7. Verrotti A, Greco R, Morgese G, Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000; 47: 385-388.
8. Christiansen C, Rodbro P, Tjellesen L. Pathophysiology behind anticonvulsant osteomalacia. Acta Neurol Scand 1983; 94: 21-28.
9. Collins N, Maher J, Cole M, Baker M, Callaghan N. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991; 78: 113-122.
10. Tsukahara H, Kimura K, Todoroki Y, Ohshima Y, Hiraoka M, Shigematsu Y, Tsukahara Y, Miura M, Mayumi M. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002; 44: 247-253.
11. 2. Zhonghua Nei Ke Za Zhi 1991; 30: 33-34, 61.
12. Erbayat Altay E, Serdaroglu A, Tumer L, Gucuyener K, Hasanoglu A. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000; 13: 933-939.
13. Jekovec-Vrhovsek M, Kocijancic A, Prezelj J. Effect of vitamin D and calcium on bone mineral density in children with CP and epilepsy in full-time care. Dev Med Child Neurol 2000; 42: 403-405.
14. Baer MT, Kozlowski BW, Blyler EM, Trahms CM, Taylor ML, Hogan MP. Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status. Am J Clin Nutr 1997; 65: 1042-1051.
15. Arai H, Ito K, Nagao K, Furutachý M. The evaluation of three different bone densitometry systems - the XR-26, QDR-1000, and DPX. Image Technol Infor Display 1990; 22: 1111-1116.
16. Ponder S, McCormick D, Fawcett HD, Palmer JL. Spinal bone mineral density in children aged 5.00 through 11.99 years. Am J Dis Child 1990; 144: 1348-1352.
17. Glastre C, Braillon P, David L, Cochat P, Meunier PJ, Delmas PD. Measurement of bone mineral content of the lumbar spine by dual energy X-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab 1990; 70: 1330-1333.
18. Sheth RD, Wesolowski CA, Jacob JC, Penney S, Hobbs GR, Riggs JE, Bodensteiner JB. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995; 127: 256-262.
19. Akin R, Okutan V, Sarici U, Altunbas A, Gokcay E. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol 1998; 19: 129-131.
20. Kafali G, Erselcan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr 1999; 38: 93-98.
21. Tsukahara H, Nakashima T, Yoshimoto M, Kuriyama M, Shigematsu Y, Hayashi S, Haruki S, Ishii Y, Sudo M. Evaluation of lumbar bone mineral density by dual energy X-ray absorptiometry. Acta Paediatr Jpn 1991; 33: 459-466.
22. Filardi S, Guerreiro CA, Magna LA, Marques Neto JF. Bone mineral density, vitamin D and anticonvulsant therapy. Arq Neuropsiquiatr 2000; 58: 616-620.
23. Goksen D, Coker M, Darcan S. Bone mineral measurements in prepubertal Turkish children. Pediatr Res 2001; 42 (Suppl): 28A (Abst).
24. Nishiyama S, Kuwahara T, Matsuda I. Decreased bone density in severely handicapped children and adults, with reference to the influence of limited mobility and anticonvulsant medication. Eur J Pediatr 1986; 144: 457-463.
25. 3 on bone-mineral content in carbamazepine-treated epileptic patients. Acta Neurol Scand 1983; 68: 424-428.
26. Gilsanz V. Bone density in children: a review of the available techniques and indications. Eur J Radiol 1998; 26: 177-182.
27. Takeshita N, Seino Y, Ishida H, Seino Y, Tanaka H, Tsutsumi C, Ogata K, Kiyohara K, Kato H, Nozawa M. Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy. Calcif Tissue Int 1989; 44: 80-85.
28. Morijiri Y, Sato T. Factors causing rickets in institutionalised handicapped children on anticonvulsant therapy. Arch Dis Child 1981; 56: 446-449.
29. 3-activating cytochrome P-450-linked monooxygenase systems. J Steroid Biochem Mol Biol 1991; 39: 479-485.
30. Jubiz W, Haussler MR, McCain TA, Tolman KG. Plasma 1,25-dihydroxyvitamin D levels in patients receiving anticonvulsant drugs. J Clin Endocrinol Metab 1977; 44: 617-621.
31. Tokita A, Matsumoto H, Morrison NA, Tawa T, Miura Y, Fukamauchi K, Mitsuhashi N, Irimoto M, Yamamori S, Miura M, Watanabe T, Kuwabara Y, Yabuta K, Eisman JA. Vitamin D receptor alleles, bone mineral density and turnover in premenopausal Japanese women. J Bone Miner Res 1996; 11: 1003-1009.